Model for the study of drug resistance in ovarian cancer
| Inventor | Institute |
|---|---|
| Kenneth H. Cowan | National Cancer Institute |
| SKU: | 161022 |
|---|---|
| Product description: | The NCI/ADR-RES cell line is a multidrug-resistant human ovarian cancer cell line derived from the OVCAR-8 parental line. It is widely used in cancer research to investigate mechanisms of chemoresistance, particularly those involving the overexpression of the MDR1 gene, which encodes the drug efflux transporter P-glycoprotein. This cell line is part of the NCI-60 panel developed by the U.S. National Cancer Institute and serves as a valuable model for evaluating anticancer agents and studying strategies to overcome multidrug resistance. Notably, NCI/ADR-RES was previously misidentified as a derivative of the MCF-7 breast cancer cell line and referred to as MCF-7/ADR, a misclassification that was later corrected through molecular and genomic profiling. |
| CRISPR: | No |
| Production details: | The MCF-7/ADR cell line was first described in 1986 by Batist et al., who developed it by exposing the MCF-7 breast cancer cell line (mis-identified) to increasing concentrations of the chemotherapeutic drug adriamycin (doxorubicin). This process led to the selection of a stable, multidrug-resistant subline that overexpressed P-glycoprotein (MDR1/ABCB1), making it a widely used model for studying drug resistance in cancer. |
| Additional notes: | Spectral karyotyping of the 59 cell lines currently in the drug screen panel demonstrates that the Ovarian tumor cell line OVCAR-8 shares a large number of karyotypic abnormalities with the NCI/ADR-RES line. |
| Cellosaurus ID: | CVCL_1452 |
| Parental cell line: | OVCAR-8 |
| Disease: | Cancer;Ovarian cancer;High Grade Serous Epithelial Ovarian cancer |
| Cat. #: | 161022 |
|---|---|
| Cancer types: | Ovarian cancer |
| Research Fields: | Cancer |
| Organism: | Human |
| Tissue: | Ovary |
| Growth properties: | Adherent |
| Cancer Types In Detail: | Gynaecologic cancer;Ovarian |
| Primary citation: | Batist G, et al. J Biol Chem. 1986 Nov 25;261(33):15544-9. PMID: 3782078 |
| Format: | Frozen |
|---|---|
| Storage conditions: | Liquid Nitrogen |
| Shipping conditions: | Dry Ice |
| Growth medium: | RPMI 1640 + 10% FBS + 50 U/mL Penicillin + 50 μg/mL Streptomycin + 1.84 μM Doxorubicin (to maintain resistance phenotype). |
| Temperature: | 37° C |
| Atmosphere: | 5% CO2 |
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.